PD-L1 regulates genomic stability via interaction with cohesin-SAl in the nucleus  

作　　者：Wen Zhang Jiali Jin Yanjin Wang Lan Fanq Liu Min Xinbo Wang Lin Ding Linjun Weng Tan Xiao Tianhua Zhou Ping Wang 

机构地区：[1]Tongji University Cancer Center,Shanghai Tenth People's Hospital of Tongji University,School of Medicine,Tongji University,Shanghai,China [2]Deportment of Cell Biology and Cancer Institute of the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,China [3]School of Life Sciences and Technology,Tongji University,Shanghai,China [4]Cancer Center,Zhejiang University,Hangzhou,China [5]Department of Molecular Genetics,University of Toronto,Toronto,ON,Canada

出　　处：《Signal Transduction and Targeted Therapy》2021年第3期608-610,共3页信号转导与靶向治疗（英文）

摘　　要：Dear Editor,Programmed death ligand-1(PD-L1)is a type 1 transmembrane protein and highly expressed in various cancers that binds to PD-1 on T cells,inhibits T cell activity and proliferation,facilitates cancer cells to escape T cell-mediated immune surveillance.Immunotherapies by PD-L1/PD-1 blockade have shown effectiveness against different cancer types and revolutionizes cancer treatment in the clinic.However,the response rate to anti-PD-L1/PD-1 antibody remains at about 15-30%as a single agent.1 Thus,there is more to understand regarding the function of PD-L1 in cancer.

关 键 词：CANCER DEATH INTERACTION 

分 类 号：R730.5[医药卫生—肿瘤]